https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/en-ukCopyright (C) 2026 newslocker.comThu, 04 Jun 2026 07:06:00 +0200 This month's update covers new approvals across oncology, respiratory medicine, infectious disease, cardiology, and dermatology.Veppanu (vepdegestrant)
The FDA approved Veppanu for the treatment of adults with estrogen...]]>https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/monthly-news-roundup-may-2026/Thu, 04 Jun 2026 07:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/monthly-news-roundup-may-2026/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/influenza-vaccine-effective-for-children-aged-2-to-5-years/Wed, 03 Jun 2026 22:59:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/influenza-vaccine-effective-for-children-aged-2-to-5-years/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/tezepelumab-reduces-need-for-oral-corticosteroids-in-adults-with-asthma/Wed, 03 Jun 2026 22:56:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/tezepelumab-reduces-need-for-oral-corticosteroids-in-adults-with-asthma/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-modest-accuracy-seen-for-existing-breast-cancer-risk-prediction-models/Wed, 03 Jun 2026 18:01:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-modest-accuracy-seen-for-existing-breast-cancer-risk-prediction-models/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-app-facilitated-palliative-care-improves-hrqol-in-advanced-cancer/Wed, 03 Jun 2026 17:57:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-app-facilitated-palliative-care-improves-hrqol-in-advanced-cancer/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/mailed-fit-kits-boost-colorectal-cancer-screening-across-racial-ethnic-groups/Wed, 03 Jun 2026 17:55:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/mailed-fit-kits-boost-colorectal-cancer-screening-across-racial-ethnic-groups/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/diagnostic-interviews-may-not-be-reliable-for-behavioral-health-diagnoses/Wed, 03 Jun 2026 17:53:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/diagnostic-interviews-may-not-be-reliable-for-behavioral-health-diagnoses/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/cardiometabolic-cardiovascular-complications-less-likely-with-hydroxychloroquine-in-dle/Wed, 03 Jun 2026 17:50:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/cardiometabolic-cardiovascular-complications-less-likely-with-hydroxychloroquine-in-dle/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/over-one-third-of-us-adults-report-more-than-one-sunburn-in-previous-12-months/Tue, 02 Jun 2026 23:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/over-one-third-of-us-adults-report-more-than-one-sunburn-in-previous-12-months/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/ats-early-nonadherence-to-cpap-does-not-predict-treatment-abandonment/Tue, 02 Jun 2026 23:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/ats-early-nonadherence-to-cpap-does-not-predict-treatment-abandonment/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/sacituzumab-govitecan-shows-encouraging-results-for-aggressive-endometrial-cancer/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/sacituzumab-govitecan-shows-encouraging-results-for-aggressive-endometrial-cancer/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/population-based-screening-can-id-children-who-progress-to-clinical-t1d/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/population-based-screening-can-id-children-who-progress-to-clinical-t1d/ Allison...]]>https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/new-open-access-tool-guides-pediatric-amblyopia-diagnosis-management/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/new-open-access-tool-guides-pediatric-amblyopia-diagnosis-management/ Phil...]]>https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/creatine-use-rose-sharply-in-us-teens-from-2019-to-2024/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/creatine-use-rose-sharply-in-us-teens-from-2019-to-2024/ John B. Doyle, M.D., from...]]>https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/celiac-disease-tied-to-higher-risk-for-solid-organ-transplants/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/celiac-disease-tied-to-higher-risk-for-solid-organ-transplants/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-teclistamab-improves-survival-in-relapsed-refractory-multiple-myeloma/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-teclistamab-improves-survival-in-relapsed-refractory-multiple-myeloma/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-selpercatinib-improves-event-free-survival-in-ret-fusion-positive-nsclc/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-selpercatinib-improves-event-free-survival-in-ret-fusion-positive-nsclc/ Mehul V. Raval, M.D., from...]]>https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/adopting-enhanced-recovery-protocols-aids-pediatric-gi-surgery-outcomes/Tue, 02 Jun 2026 17:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/adopting-enhanced-recovery-protocols-aids-pediatric-gi-surgery-outcomes/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-glp-1-receptor-agonist-initiation-cuts-metastatic-progression-across-cancer-types/Mon, 01 Jun 2026 21:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-glp-1-receptor-agonist-initiation-cuts-metastatic-progression-across-cancer-types/https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-fasting-before-and-after-chemo-may-up-efficacy-in-serous-ovarian-cancer/Mon, 01 Jun 2026 21:06:00 +0200https://www.newslocker.com/en-uk/profession/pharmaceutical-industry/asco-fasting-before-and-after-chemo-may-up-efficacy-in-serous-ovarian-cancer/